Drug Profile
MPC 0920
Alternative Names: MPC-0920Latest Information Update: 25 Sep 2009
Price :
$50
*
At a glance
- Originator Myriad Pharmaceuticals
- Class Anticoagulants; Antithrombotics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 25 Sep 2009 Discontinued - Phase-I for Thrombosis in USA (PO)
- 29 Jan 2008 Myriad completes a phase I trial in volunteers in USA
- 17 Aug 2007 MPC 0920 is still in phase I trials for thrombosis in the US